Schweinfurthin induces ICD without ER stress and caspase activation

References

• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–19. Epub 2015/04/11. PubMed PMID: 25860605; PMCID: PMC5905674. doi: 10.1016/j.cell.2015.03.030.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (New York, NY). 2018;359(6382):1350–1355. Epub 2018/03/24. PubMed PMID: 29567705; PMCID: PMC7391259. doi: 10.1126/science.aar4060.
   Google Scholar
• Przybylski DJ, Bergsbaken JJ, Piccolo JK. Unleashing the power of immunotherapy and targeted therapy combinations: advancing cancer care or discovering unknown toxicities? J Oncol Pharm Prac: Off Pub Inter Soc Oncol Pharm Prac. 2021;27(4):930–938. Epub 2021/01/08. PubMed PMID: 33406979. doi: 10.1177/1078155220984235.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. Epub 2021/02/23. PubMed PMID: 33616314. doi: 10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, Qin S, Zhang H, Yu F. Immunogenic cell death induction by ionizing radiation. Frontiers in Immunology. 2021;12:705361. Epub 2021/09/08. PubMed PMID: 34489957; PMCID: PMC8417736. doi: 10.3389/fimmu.2021.705361.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928. Epub 2019/05/16. PubMed PMID: 31086347. doi: 10.1038/s41591-019-0432-4.
   PubMed Web of Science ®Google Scholar
• Feola S, Russo S, Ylösmäki E, Cerullo V. Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther. 2021;236:108103. Epub 2021/12/27. PubMed PMID: 34954301. doi: 10.1016/j.pharmthera.2021.108103.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, Ni C. The immunomodulatory effects of endocrine therapy in breast cancer. Journal of Experimental & Clinical Cancer Research: CR. 2021;40(1):19. Epub 2021/01/09. PubMed PMID: 33413549; PMCID: PMC7792133. doi: 10.1186/s13046-020-01788-4.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. Epub 2021/03/21. PubMed PMID: 33741032; PMCID: PMC7977302. doi: 10.1186/s13045-021-01056-8.
   PubMed Web of Science ®Google Scholar
• Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. Epub 2022/01/23. PubMed PMID: 35062949. doi: 10.1186/s12943-021-01489-2.
   PubMed Web of Science ®Google Scholar
• Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3. Epub 2022/01/26. PubMed PMID: 35074008. doi: 10.1186/s40164-022-00257-2.
   PubMed Web of Science ®Google Scholar
• Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther. 2013;93(4):299–301. Epub 2013/03/21. PubMed PMID: 23511784. doi: 10.1038/clpt.2012.236.
   PubMed Web of Science ®Google Scholar
• Chabner BA. NCI-60 Cell Line Screening: a Radical Departure in its Time. J Natl Cancer Inst. 2016;108(5):djv388. Epub 2016/01/13. PubMed PMID: 26755050. doi: 10.1093/jnci/djv388.
   PubMedGoogle Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813–823. PubMed PMID: ISI:000241303000017. doi:10.1038/nrc1951.
   PubMed Web of Science ®Google Scholar
• Covell DG, Huang RL, Wallqvist A. Anticancer medicines in development: assessment of bioactivity profiles within the national cancer institute anticancer screening data. Mol Cancer Ther. 2007;6(8):2261–2270. PubMed PMID: WOS:000248663000013. doi:10.1158/1535-7163.mct-06-0787.
   PubMed Web of Science ®Google Scholar
• Beutler JA, Shoemaker RH, Johnson T, Boyd MR. Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod. 1998;61(12):1509–1512. PubMed PMID: ISI:000077879700011. doi:10.1021/np980208m.
   PubMed Web of Science ®Google Scholar
• Koubek EJ, Weissenrieder JS, Neighbors JD, Hohl RJ. Schweinfurthins: lipid modulators with promising anticancer activity. Lipids. 2018;53(8):767–784. Epub 2018/10/20. PubMed PMID: 30334267. doi: 10.1002/lipd.12088.
   PubMed Web of Science ®Google Scholar
• Beutler JA, Jato J, Cragg GM, Boyd MR. Schweinfurthin D, a cytotoxic stilbene from Macaranga schweinfurthii. Nat Prod Lett. 2000;14(5):399–404. PubMed PMID: ISI:000089742200012. doi:10.1080/10575630008043774.
   Web of Science ®Google Scholar
• Klausmeyer P, Van QN, Jato J, McCloud TG, Beutler JA. Schweinfurthins I and j from Macaranga schweinfurthii. J Nat Prod. 2010;73(3):479–481. PubMed PMID: WOS:000275885000035. doi:10.1021/np9006348.
   PubMed Web of Science ®Google Scholar
• Yoder BJ, Cao S, Norris A, Miller JS, Ratovoson F, Razafitsalama J, Andriantsiferana R, Rasamison VE, Kingston DG. Antiproliferative prenylated stilbenes and flavonoids from Macaranga alnifolia from the Madagascar rainforest. J Nat Prod. 2007;70(3):342–346. Epub 2007/02/28. PubMed PMID: 17326683; PMCID: PMC2614403. doi: 10.1021/np060484y.
   PubMed Web of Science ®Google Scholar
• Thoison O, Hnawia E, Gueritte-Voegelein F, Sevenet T. Plants of new-caledonia .140. Vedelianin, a Hexahydroxanthene derivative isolated from Macaranga vedeliana. Phytochemistry. 1992 PubMed PMID: ISI:A1992HM38900080;31(4):1439–1442. doi:10.1016/0031-9422(92)80315-6.
   Web of Science ®Google Scholar
• Beutler JA, Jato J, Cragg G, Wiemer DF, Neighbors JD, Salnikova MS, Hollingshead M, Scudiero DA, and McCloud TG. The Schweinfurthins: issues in development of a plant-derived anticancer lead. In: Bogers RJ editor. Medicinal and aromatic plants. New York, NY: Springer; 2005. p. 301–309.
   Google Scholar
• Kodet JG, Beutler JA, Wiemer DF. Synthesis and structure activity relationships of schweinfurthin indoles. Bioorg Med Chem. 2014;22(8):2542–2552. PubMed PMID: WOS:000334338000019. doi:10.1016/j.bmc.2014.02.043.
   PubMed Web of Science ®Google Scholar
• Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)– and (S,S,S)–Schweinfurthin F: differences of bioactivity in the enantiomeric series. Biorg Med Chem Lett. 2007;17(4):911–915. doi:10.1016/j.bmcl.2006.11.096.
   PubMed Web of Science ®Google Scholar
• Neighbors JD, Salnikova MS, Beutler JA, Wiemer DF. Synthesis and structure-activity studies of schweinfurthin B analogs: evidence for the importance of a D-ring hydrogen bond donor in expression of differential cytotoxicity. Bioorg Med Chem. 2006;14(6):1771–1784. Epub 2005/11/18. PubMed PMID: 16290161. doi: 10.1016/j.bmc.2005.10.025.
   PubMed Web of Science ®Google Scholar
• Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure. Bioorg Med Chem. 2010;18(4):1676–1683. PubMed PMID: WOS:000274425500033. doi:10.1016/j.bmc.2009.12.063.
   PubMed Web of Science ®Google Scholar
• Burgett AWG, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K, Okubo S, Fortner KC, Mimaki Y, Kuroda M, et al. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol. 2011;7(9):639–647. PubMed PMID: WOS:000294381400015. doi:10.1038/nhembio.625.
   PubMed Web of Science ®Google Scholar
• Bao X, Zheng W, Sugi NH, Agarwala K, Xu Q, Wang Z, Tendyke K, Lee W, Parent L, Wei L, et al. Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking. Cancer Biol Ther. 2015;16(4):1–13. doi:10.1080/15384047.2015.1019184.
   PubMed Web of Science ®Google Scholar
• Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ. 3-Deoxyschweinfurthin B lowers cholesterol levels by decreasing synthesis and increasing export in cultured cancer cell lines. Lipids. 2015:1–13. doi:10.1007/s11745-015-4083-z.
   Web of Science ®Google Scholar
• Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, and Robertson GP, et al. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 2018;8(2):e1539614–5. PMCID: PMC Journal - In Process.
   PubMed Web of Science ®Google Scholar
• Stevens JW, Meyerholz DK, Neighbors JD, Morcuende JA. 5’-methylschweinfurthin G reduces chondrosarcoma tumor growth Journal of orthopaedic research: official publication of the orthopaedic research society. J Orthop Res: Off Pub Orthop Res Soc. 2018;36(4):1283–1293. Epub 2017/09/30. PubMed PMID: 28960476. doi: 10.1002/jor.23753.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013. Epub 2020/11/28. PubMed PMID: 33243969; PMCID: PMC7691519 Samsara Therapeutics. G.K. has been holding research contracts with Bayer Healthcare, Genentech, Glaxo Smyth Kline, Institut Mérieux, Lytix Pharma, PharmaMar, Sotio, and Vasculox. He is on the Board of Directors of the Bristol Myers Squibb Foundation France and is a scientific co-founder of everImmune, Samsara Therapeutics, and Therafast Bio. L.G. received research support from Lytix and Phosplatin, consulting fees from OmniSEQ, Astra Zeneca, Inzen, and the Luke Heller TECPR2 Foundation, and is a member of the Scientific Advisory Committee of Boehringer Ingelheim, The Longevity Labs, and OmniSEQ. All other authors have no conflicts to declare. doi: 10.1038/s41419-020-03221-2.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kasikova L, Truxova I, Laco J, Skapa P, Ryska A, Spisek R. Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer. Immunol Lett. 2018;193:25–34. Epub 2017/11/28. PubMed PMID: 29175313. doi: 10.1016/j.imlet.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. Epub 2012/11/16. PubMed PMID: 23151605. doi: 10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321–334. Epub 2005/10/22. PubMed PMID: 16239148. doi: 10.1016/j.cell.2005.08.032.
   PubMed Web of Science ®Google Scholar
• Radogna F, Diederich M. Stress-induced cellular responses in immunogenic cell death: implications for cancer immunotherapy. Biochem Pharmacol. 2018;153:12–23. PubMed PMID: WOS:000434102600003. doi:10.1016/j.bcp.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. Epub 2012/11/20. PubMed PMID: 23157435. doi: 10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Wiersma VR, Michalak M, Abdullah TM, Bremer E, Eggleton P. Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol. 2015;5 PubMed PMID: WOS:000359071800001. doi:10.3389/fonc.2015.00007.
   Web of Science ®Google Scholar
• Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28(5):578–590. Epub 2009/01/24. PubMed PMID: 19165151; PMCID: PMC2657583. doi: 10.1038/emboj.2009.1.
   PubMed Web of Science ®Google Scholar
• Madeo F, Durchschlag M, Kepp O, Panaretakis T, Zitvogel L, Fröhlich KU, Kroemer G. Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals. Cell Cycle (Georgetown, Tex). 2009;8(4):639–642. Epub 2009/02/03. PubMed PMID: 19182525. doi: 10.4161/cc.8.4.7794.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Moriya M, Baba T, Michikawa Y, Yamanobe T, Arai K, Okinaga S, Kobayashi T. An endoplasmic reticulum protein, calreticulin, is transported into the acrosome of rat sperm. Exp Cell Res. 1993;205(1):101–110. Epub 1993/03/01. PubMed PMID: 8453984. doi: 10.1006/excr.1993.1063.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshio S, Tamura A, Okinaga S, Arai K. Antisera to calreticulin inhibits sperm motility in mice. Biochem Biophys Res Commun. 1992;186(2):984–990. Epub 1992/07/31. PubMed PMID: 1497681. doi: 10.1016/0006-291x(92)90843-a.
   PubMed Web of Science ®Google Scholar
• Park BJ, Lee DG, Yu JR, Jung SK, Choi K, Lee J, Lee J, Kim YS, Lee JI, Kwon JY, et al. Calreticulin, a calcium-binding molecular chaperone, is required for stress response and fertility in Caenorhabditis elegans. Mol Biol Cell. 2001;12(9):2835–2845. Epub 2001/09/13. PubMed PMID: 11553721; PMCID: PMC59717. doi: 10.1091/mbc.12.9.2835.
   PubMed Web of Science ®Google Scholar
• Radogna F, Dicato M, Diederich M. Natural modulators of the hallmarks of immunogenic cell death. Biochem Pharmacol. 2019;162:55–70. Epub 2019/01/08. PubMed PMID: 30615863. doi: 10.1016/j.bcp.2018.12.016.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–4865. Epub 2019/06/19. PubMed PMID: 31210425; PMCID: PMC6653385. doi: 10.1111/jcmm.14356.
   PubMed Web of Science ®Google Scholar
• Vaes RDW, Hendriks LEL, Vooijs M, De Ruysscher D. Biomarkers of radiotherapy-induced immunogenic cell death. Cells. 2021;10(4):930. Epub 2021/05/01. PubMed PMID: 33920544; PMCID: PMC8073519. doi: 10.3390/cells10040930.
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene. 1998;16(26):3397–3402. Epub 1998/08/06. PubMed PMID: 9692547. doi: 10.1038/sj.onc.1201881.
   PubMed Web of Science ®Google Scholar
• Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122(2):337–341. Epub 2004/03/11. PubMed PMID: 15009714; PMCID: PMC2586668. doi: 10.1046/j.0022-202X.2004.22243.x.
   PubMed Web of Science ®Google Scholar
• Feng R, Zhao H, Xu J, Shen C. CD47: the next checkpoint target for cancer immunotherapy. Crit Rev Oncol Hematol. 2020;152:103014. Epub 2020/06/15. PubMed PMID: 32535479. doi: 10.1016/j.critrevonc.2020.103014.
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;15(9):1499–1509. Epub 2008/05/10. PubMed PMID: 18464797. doi: 10.1038/cdd.2008.67.
   PubMed Web of Science ®Google Scholar
• Jessop CE, Chakravarthi S, Garbi N, Hämmerling GJ, Lovell S, Bulleid NJ. ERp57 is essential for efficient folding of glycoproteins sharing common structural domains. EMBO J. 2007;26(1):28–40. Epub 2006/12/16. PubMed PMID: 17170699; PMCID: PMC1782378. doi: 10.1038/sj.emboj.7601505.
   PubMed Web of Science ®Google Scholar
• Kusaczuk M. Tauroursodeoxycholate-bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cells. 2019;8(12):1471. Epub 2019/11/24. PubMed PMID: 31757001; PMCID: PMC6952947. doi: 10.3390/cells8121471.
   PubMed Web of Science ®Google Scholar
• Mahameed M, Wilhelm T, Darawshi O, Obiedat A, Tommy WS, Chintha C, Schubert T, Samali A, Chevet E, Eriksson LA, et al. The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death Dis. 2019;10(4):300. Epub 2019/04/02. PubMed PMID: 30931942; PMCID: PMC6443726 Ltd. The other authors declare that they have no conflict of interest. doi: 10.1038/s41419-019-1523-3.
   PubMedGoogle Scholar
• van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31(1):1–9. Epub 1998/02/05. PubMed PMID: 9450519. doi: 10.1002/(sici)1097-0320(19980101)31:1<1::aid-cyto1>3.0.co;2-r.
   PubMedGoogle Scholar
• Schmid I, Krall WJ, Uittenbogaart CH, Braun J, Giorgi JV. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry. 1992;13(2):204–208. Epub 1992/01/01. PubMed PMID: 1547670. doi: 10.1002/cyto.990130216.
   PubMedGoogle Scholar
• Van Noorden CJ. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem. 2001;103(3):241–251. Epub 2001/08/03. PubMed PMID: 11482370. doi: 10.1078/0065-1281-00601.
   PubMed Web of Science ®Google Scholar
• Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol. 1999;178(2):133–143. Epub 1999/02/27. PubMed PMID: 10048577. doi: 10.1002/(sici)1097-4652(199902)178:2<133::aid-jcp2>3.0.co;2-5.
   PubMed Web of Science ®Google Scholar
• Chardin P, McCormick F. Brefeldin A: the advantage of being uncompetitive. Cell. 1999;97(2):153–155. Epub 1999/04/29. PubMed PMID: 10219235. doi: 10.1016/s0092-8674(00)80724-2.
   PubMed Web of Science ®Google Scholar
• Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24(4):311–318. Epub 2013/06/22. PubMed PMID: 23787159. doi: 10.1016/j.cytogfr.2013.05.001.
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Giordanetto F, Tesniere A, Vitale I, Martins I, Schlemmer F, Adjemian S, Zitvogel L, Kroemer G. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle (Georgetown, Tex). 2009;8(23):3971–3977. Epub 2009/11/11. PubMed PMID: 19901557. doi: 10.4161/cc.8.23.10191.
   PubMed Web of Science ®Google Scholar
• Giglio P, Gagliardi M, Tumino N, Antunes F, Smaili S, Cotella D, Santoro C, Bernardini R, Mattei M, Piacentini M, et al. PKR and GCN2 stress kinases promote an ER stress-independent eIF2α phosphorylation responsible for calreticulin exposure in melanoma cells. Oncoimmunology. 2018;7(8):e1466765. Epub 2018/09/18. PubMed PMID: 30221067; PMCID: PMC6136861. doi: 10.1080/2162402x.2018.1466765.
   PubMed Web of Science ®Google Scholar
• Gomes-da-Silva LC, Zhao L, Bezu L, Zhou H, Sauvat A, Liu P, Durand S, Leduc M, Souquere S, Loos F, et al. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO J. 2018;37(13). Epub 2018/05/29. PubMed PMID: 29807932; PMCID: PMC6028029. doi: 10.15252/embj.201798354.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. Epub 2006/12/26. PubMed PMID: 17187072. doi: 10.1038/nm1523.
   PubMed Web of Science ®Google Scholar
• Lam STT, Lim CJ. Cancer biology of the endoplasmic reticulum lectin chaperones calreticulin, calnexin and PDIA3/ERp57. Vol. 59 . Agellon L.B, Michalak M editors. Progress in Molecular and Subcellular Biology. New York, NY: Springer Cham. 181–196; 2021. doi: 10.1007/978-3-030-67696-4_9.
   Google Scholar
• Liu CC, Leclair P, Pedari F, Vieira H, Monajemi M, Sly LM, Reid GS, Lim CJ. Integrins and ERp57 coordinate to regulate cell surface calreticulin in immunogenic cell death. Front Oncol. 2019;9:411. Epub 2019/06/14. PubMed PMID: 31192123; PMCID: PMC6546883. doi: 10.3389/fonc.2019.00411.
   PubMed Web of Science ®Google Scholar
• Werthmöller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis. 2015;6(5):e1761. Epub 2015/05/15. PubMed PMID: 25973681; PMCID: PMC4669707. doi: 10.1038/cddis.2015.129.
   PubMedGoogle Scholar
• Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31(5):1062–1079. Epub 2012/01/19. PubMed PMID: 22252128; PMCID: PMC3298003. doi: 10.1038/emboj.2011.497.
   PubMed Web of Science ®Google Scholar
• Jagot-Lacoussiere L, Kotula E, Villoutreix BO, Bruzzoni-Giovanelli H, Poyet JL. A cell-penetrating peptide targeting AAC-11 specifically induces cancer cells death. Cancer Res. 2016;76(18):5479–5490. Epub 2016/07/14. PubMed PMID: 27406828. doi: 10.1158/0008-5472.can-16-0302.
   PubMed Web of Science ®Google Scholar
• Pasquereau-Kotula E, Habault J, Kroemer G, Poyet JL. The anticancer peptide RT53 induces immunogenic cell death. PLoS One. 2018;13(8):e0201220. Epub 2018/08/07. PubMed PMID: 30080874; PMCID: PMC6078289 the donor) of an instrument to GK. This does not alter our adherence to PLOS ONE policies on sharing data and materials. doi: 10.1371/journal.pone.0201220.
   PubMed Web of Science ®Google Scholar
• Cao L, Mu W. Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications. Pharmacological Research. 2021;163:105297. Epub 2020/11/13. PubMed PMID: 33181319; PMCID: PMC7962892. doi: 10.1016/j.phrs.2020.105297.
   PubMed Web of Science ®Google Scholar
• Zhu H, Sun A. Programmed necrosis in heart disease: molecular mechanisms and clinical implications. J Mol Cell Cardiol. 2018;116:125–134. Epub 2018/02/10. PubMed PMID: 29426003. doi: 10.1016/j.yjmcc.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Moosavi B, Gao M, Zhu XL, Yang GF. The anti-cancer compound Schweinfurthin A targets Osh2 and disrupts lipid metabolism in the yeast model. Bioorg Chem. 2020;94:103471. Epub 2019/12/10. PubMed PMID: 31813476. doi: 10.1016/j.bioorg.2019.103471.
   PubMed Web of Science ®Google Scholar
• Péresse T, Kovacs D, Subra M, Bigay J, Tsai MC, Polidori J, Gautier R, Desrat S, Fleuriot L, Debayle D, et al. Molecular and cellular dissection of the oxysterol-binding protein cycle through a fluorescent inhibitor. J Biol Chem. 2020;295(13):4277–4288. Epub 2020/02/23. PubMed PMID: 32075908; PMCID: PMC7105299. doi: 10.1074/jbc.RA119.012012.
   PubMed Web of Science ®Google Scholar
• Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ. Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification. Mol Pharmacol. 2012;82(1):9–16. PubMed PMID: WOS:000305470000002. doi:10.1124/mol.111.077107.
   PubMed Web of Science ®Google Scholar
• Niu X, Chen L, Li Y, Hu Z, He F. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC. Semin Cancer Biol. 2022; Epub 2022/03/16. PubMed PMID: 35288298. doi: 10.1016/j.semcancer.2022.03.009.
   Web of Science ®Google Scholar
• Demuynck R, Efimova I, Naessens F, Krysko DV. Immunogenic ferroptosis and where to find it? Journal for Immunotherapy of Cancer. 2021;9(12):e003430. Epub 2021/12/15. PubMed PMID: 34903554; PMCID: PMC8671998. doi: 10.1136/jitc-2021-003430.
   PubMed Web of Science ®Google Scholar
• Rabouw HH, Visser LJ, Passchier TC, Langereis MA, Liu F, Giansanti P, van Vliet ALW, Dekker JG, van der Grein SG, Saucedo JG, et al. Inhibition of the integrated stress response by viral proteins that block p-eIF2-eIF2B association. Nature Microbiology. 2020;5(11):1361–1373. Epub 2020/07/22. PubMed PMID: 32690955. doi: 10.1038/s41564-020-0759-0.
   PubMed Web of Science ®Google Scholar
• Tagaram HR, Watson AM, Lemonnier FA, Staveley-O’Carroll K, Tevethia SS, Schell TD. An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. Virology. 2008;376(1):183–190. Epub 2008/04/12. PubMed PMID: 18402997; PMCID: PMC2464359. doi: 10.1016/j.virol.2008.02.033.
   PubMed Web of Science ®Google Scholar